5

10


Claims

- 1. Use of a GLP-1 agonist for the manufacture of a medicament for lowering total serum lipids.
- 2. Use of a GLP-1 agonist for the manufacture of a medicament for lowering LDL.
- 3. Use of a GLP-1 agonist for the manufacture of a medicament for lowering smal, dense LDL
- 4. Use of a GLP-1 agonist for the manufacture of a medicament for lowering VLDL.
- 5. Use of a GLP-1 agonist for the manufacture of a medicament for lowering triglycerides.
- 15 6. Use of a GLP-1 agonist for the manufacture of a medicament for lowering cholesterol.
 - 7. Use of a GLP-1 agonist for the manufacture of a medicament for increasing HDL.
- 8. Use of a GLP-1 agonist for the manufacture of a medicament for lowering plasma levels of Lp(a) in a human.
 - 9. Use of a GLP-1 agonist for the manufacture of a medicament for inhibiting generation of apo(a) in a human.
- 25 10. Use of a GLP-1 agonist for the manufacture of a medicament for treating dyslipidemia.
 - 11. The use according to any one of claims 1-10 wherein the GLP-1 agonist binds to a GLP-1 receptor with an affinity constant, K_D , below 1 μ M.
- 12. The use according to any one of claims 1-11 wherein the GLP-1 agonist is selected from Arg^{26} , $Lys^{34}(N-\epsilon-(\gamma-Glu(N-\alpha-hexadecanoyl)))-GLP-1(7-37)$, Arg^{34} , $Lys^{26}(N-\epsilon-(\gamma-Glu(N-\alpha-hexadecanoyl)))-GLP-1(7-37)$, exendin-3, exendin-4, Val^8 -GLP-1(7-37), Thr^8 GLP-1(7-37), Met^8 GLP-1(7-37), Gly^8 -GLP-1(7-37).

5

15

30



14. A method of lowering LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

subject an effective amount of a GLP-1 agonist.

- 15. A method of lowering small, dense LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist
- 10 16. A method of lowering VLDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
 - 17 A method of lowering triglycerides, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
 - 18. A method of lowering cholesterol, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 19. A method of increasing HDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist. 20
 - 20. A method of inhibiting generation of apo(a) in vitro or in vivo by administering a GLP-1 agonist.
- 25 21. A method of lowering plasma levels of Lp(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.
 - 22. A method of inhibiting generation of apo(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.
 - 23 A method for treating dyslipideamia which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 24 The method according to any one of claims 13-23 wherein the GLP-1 agonist binds to a GLP-1 receptor with an affinity constant, K_D , below 1 μM . 35

